Table 4 The relationship between clinical characteristics and overall survival in HCC patients based on the stratification with the TNM staging system: Cox’s regression analysis
Variable | TNM early stage ( n = 71) | TNM advanced stage ( n = 153) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
P value | Hazard ratio | 95% CI | P value | P value | Hazard ratio | 95% CI | P value | |||||
Age | 0.821 | 1.001 | 0.978–1.025 | 0.920 | 0.075 | 0.975 | 0.956–0.995 | 0.016 | ||||
Sex | 0.158 | 3.946 | 1.332–11.690 | 0.013 | 0.372 | 1.891 | 0.641–5.577 | 0.248 | ||||
HBV DNA (log 10 IU/mL) | 0.408 | – | – | – | 0.328 | – | – | – | ||||
ALT | 0.445 | – | – | – | 0.994 | – | – | – | ||||
Cycles of TACE | 0.885 | – | – | – | 0.070 | 1.305 | 0.836–2.037 | 0.242 | ||||
AST | 0.016 | 1.004 | 0.996–1.012 | 0.363 | 0.001 | 1.002 | 0.999–1.005 | 0.201 | ||||
ALB | 0.149 | – | – | – | 0.066 | 0.945 | 0.893–1.000 | 0.051 | ||||
TBIL | 0.711 | – | – | – | 0.024 | 1.008 | 0.982–1.035 | 0.555 | ||||
AFP | 0.022 | 2.087 | 0.920–4.736 | 0.078 | 0.067 | 1.144 | 0.741–1.767 | 0.545 | ||||
APTT | 0.709 | – | – | – | 0.068 | 0.988 | 0.942–1.037 | 0.633 | ||||
Antiviral treatment | 0.012 | 0.372 | 0.183–0.756 | 0.006 | 0.219 | – | – | – | ||||
Local ablation | 0.005 | 0.280 | 0.136–0.577 | 0.001 | <0.001 | 0.211 | 0.095–0.472 | <0.001 | ||||
Resection | 0.023 | 0.152 | 0.049–0.473 | 0.001 | 0.008 | 0.308 | 0.118–0.801 | 0.016 | ||||
HBeAg | 0.958 | – | – | – | 0.621 | – | – | – | ||||
PT | 0.241 | – | – | – | 0.765 | – | – | – | ||||
Sorafenib therapy | 0.943 | – | – | – | 0.782 | – | – | – | ||||
Chemotherapeutic agents (epirubicin only: >2 agents) | 0.211 | – | – | – | 0.073 | 0.881 | 0.540–1.439 | 0.613 | ||||